Everest Medicines
高管
查看带有其 14 名主要高管的组织结构图
Everest Medicines 搜索最多的简介
- Yongqing Luo, Executive Director and Chief Executive Officer
- Wei Fu, Chairman of the Board
- Shidong Jiang, Independent Non-Executive Directors
高管在Everest Medicines变化
- Sandra Zeng已作为Chief Medical Officer加入公司 (新闻发布的2024三月18号).
- Rico Liang已作为Chief Product Officer加入公司 (新闻发布的2024三月18号).
创建提醒
跟踪 Everest Medicines 的高管变动
药店
Everest Medicines 拥有 1,837 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Everest Medicines 的最新新闻稿
- Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients – Everest Medicines
- Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients – Everest Medicines
- Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy – Everest Medicines
- Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in “Kidney 360” Magazine – Everest Medicines
- Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy – Everest Medicines
- Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in “Kidney 360” Magazine – Everest Medicines
- Everest Medicines Announces Attendance at the Following September Investor Conferences – Everest Medicines
- Everest Medicines Announces Interim Results for First Half of 2024 – Everest Medicines
- Everest Medicines Announces Interim Results for First Half of 2024 – Everest Medicines
- Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 – Everest Medicines
- View more press releases Close
通过电子邮件
